Oxlumo
(Lumasiran)Phase 2RNA therapy
Alnylam PharmaceuticalsOxlumo is one of 3 small molecule programs targeting Haemodialysis. It is currently in Phase 2.
1
Indications
8
Total Trials
1
Active Trials
2
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Haemodialysis
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsPreclinical
Oxlumo
Alnylam PharmaceuticalsPhase 2
Slow Sodium
SSt George's, University of London
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Primary Hyperoxaluria Type 16 trials
Show 3 more trials
Kidney Stone1 trial
Haemodialysis1 trial
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
Recruiting·—·Phase 2·NCT06225544·50 enrolled
Regulatory
FDA Approval Timeline[4]
Nov 23, 2020
OXLUMO
NDA NDA214103
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lumasiran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Oxlumo. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy[2]
- Highest Phase
- Phase 2[1]
- Company